Overall, this study is the first to discover that the combination of sodium butyrate with an anti-PD-1 antibody demonstrates significant potential in treating gliomas by modulating immune responses and affecting gut microbiota, providing insights into overcoming the limitations of current glioma clinical treatments. This evidence concerns the gene PDCD1 and central nervous system cancer.